Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma; Eosinophilic Clear all
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

NCT05095116
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011 3 mg HS
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years and older
U.S. locations
35
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Camarillo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 2:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

NCT03052725
View directory record Official record
Conditions
Eosinophils, Asthma
Interventions
reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 23, 2026, 2:57 AM EDT
Not yet recruiting Phase 4 Interventional

Fasenra: An Asthma Study

NCT07654842
View directory record Official record
Conditions
Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Interventions
Budesonide-albuterol, Benralizumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

NCT01285323
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed No phase listed Observational Results available

Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease

NCT01634620
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NIOX MINO® Instrument (09-1100)
Device
Lead sponsor
Aerocrine AB
Industry
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Sanford, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

NCT03299686
View directory record Official record
Conditions
Asthma
Interventions
CJM112, Placebo to CJM112
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Fullerton, California • Riverside, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576
View directory record Official record
Conditions
Asthma
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 23, 2026, 2:57 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
89
States / cities
Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

NCT03469934
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Etokimab, Placebo
Biological · Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Autoinjector in Asthmatics

NCT03099096
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

NCT00587288
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
24
States / cities
Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

NCT05634746
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
59
States / cities
Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 2:57 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

NCT06270576
View directory record Official record
Conditions
Asthma; Eosinophilic, Asthma
Interventions
Lipopolysaccharides
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Jul 23, 2026, 2:57 AM EDT
Completed No phase listed Observational

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

NCT05180357
View directory record Official record
Conditions
Severe Eosinophilic Asthma, Nasal Polyps
Interventions
FASENRA(benralizumab)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Jul 23, 2026, 2:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
KT-621, Placebo
Drug · Other
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Lancaster, California • Long Beach, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jul 23, 2026, 2:57 AM EDT